See the DrugPatentWatch profile for Skytrofa
What orphan drug exclusivity does Skytrofa have?
Skytrofa (somapacitan-beco) received orphan drug designation, which can give a sponsor additional marketing protection through the U.S. orphan-drug exclusivity pathway. For orphan drugs, that exclusivity is generally triggered when the drug is approved for its orphan indication and can block FDA approval of “the same drug” for the same orphan indication for a defined period, unless specific exceptions apply [1].
How long is orphan drug exclusivity in the U.S.?
In the U.S., orphan drug exclusivity is typically 7 years from the date of FDA approval for the orphan indication [1].
Does orphan exclusivity cover all uses, or only the specific orphan indication?
Orphan drug exclusivity is tied to the approved orphan indication. It does not automatically prevent approval of the drug for other, non-orphan uses. The protection is for a specific “orphan drug” and its specific orphan indication as approved by FDA [1].
When can orphan exclusivity be reduced or lost?
Orphan exclusivity is not always absolute. It can be reduced or forfeited if certain regulatory conditions are met, such as if the sponsor fails to maintain the drug’s orphan-drug designation criteria or if the drug no longer meets the definition of being for a disease or condition that qualifies as rare [1].
How does orphan exclusivity interact with patent exclusivity and other exclusivities?
Orphan drug exclusivity is different from patent protection and from other marketing exclusivities (like pediatric exclusivity or brand exclusivity/Orange Book barriers). Patent status can still limit competitors even after orphan exclusivity ends, depending on what patents are listed and when they expire or are cleared [1].
When would competitors potentially be able to market alternatives?
Timing for market entry depends on multiple layers: when the 7-year orphan exclusivity clock ends for the specific orphan indication, plus whether any relevant patents block approval or launch. If orphan exclusivity ends, competitors still must obtain FDA approval for their version of the drug/indication and navigate any patent protections and other regulatory requirements [1].
What to look up to get the exact Skytrofa exclusivity end date
To determine the exact end date for Skytrofa’s orphan-drug exclusivity for its orphan indication, you typically need the FDA approval date for the orphan indication and then add the 7-year exclusivity period (subject to any exceptions or forfeiture). The operative date is tied to FDA approval for the orphan indication [1].
Sources
- U.S. Food & Drug Administration (FDA), Orphan Drug Designation and Approval information (7-year orphan drug exclusivity and related rules). https://www.fda.gov/industry/designating-or-using-drugs-treatment-rare-diseases-conditions/orphan-drug-designation-and-approval